Overview

Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of developing coronary heart disease in the next 10 years. The investigators will calculate the change in risk of developing coronary heart disease using the Framingham score. The Framingham score is a mathematical equation that includes the following information: Age, Gender, Diabetes status, Smoking status, Lipids, Blood Pressure. The Framingham score estimates how likely it is that someone will develop coronary heart disease over the next 10 years.
Phase:
Phase 3
Details
Lead Sponsor:
Ramesh Prasad
Collaborator:
Hoffmann-La Roche
Treatments:
Calcineurin Inhibitors
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid